Summary
4′-0-tetrahydropyranyladriamycin hydrochloride (THP-ADM) is a new anthracycline derivative. The antitumor activity of THP-ADM was tested on 51 human tumor samples representing ten different tumor types in in vitro colony assay method. Tested tumors were: 26 cases of ovarian cancer, 8 cases of breast cancer, 6 cases of colorectal cancer, 3 cases of endometrial cancer, 2 cases each with gastric cancer and sarcoma, and another 4 cases. An in vitro colony assay was done in soft agar as described by Hamburger & Salmon. The criteria for in vitro sensitivity was defined as a 70 percent or greater reduction in the number of colonies after a 1-h exposure to drugs. The selected concentrations of THP-ADM for assay were 0.05, 0.5, and 1.0 μg/ml. The sensitivity rates for THP-ADM in each dose were: 0.05 μg/ml (7/19, 37%), 0.5 μg/ml (10/51, 20%), and 1.0 μg/ml (12/19, 63%). In vitro sensitivity of adriamycin (0.04 μg/ml) was simultaneously tested in 49 cancer patients. Five out of 25 ovarian cancer patients (20%) showed responses to adriamycin and an overall response rate was 12% (6/49). These data indicate that THP-ADM has an antitumor activity against various cancers and it is comparable to that of adriamycin.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Umezawa H, Takahashi Y, Kinoshita M, Naganawa H, Masuda T, Ishizuka M, Tatsuta K, Takeuchi T: Tetrahydropyranyl derivatives of daunomycin and adriamycin. J Antibiot (Tokyo) 32:1082–1084, 1979
Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y: 4′-0-tetrahydropyranyladriamycin as a potential new antitumor agent. Cancer Res 42:1462–1467, 1982
Dantchev D, Paintrand M, Hayat M, Bourut C, Mathé G: Low heart and skin toxicity of a tetrahydropyranyl derivative of adriamycin (THP-ADM) as observed by electron and light microscopy. J Antibiot (Tokyo) 32:1085–1086, 1979
Ogawa M, Miyamoto H, Inagaki J, Horikoshi N, Ezaki K, Inoue K, Ikeda K, Usui N, Nakada H: Phase I clinical trial of a new anthracycline: 4′-0-tetrahydropyranyl adriamycin. Jap J Clin Oncol 10(1):129–133, 1983
Hamburger AW, Salmon SE: Primary bioassay of human tumor stem cells. Science 197:461–463, 1977
Hamburger AW, Salmon SE: Primary bioassay of human myeloma stem cells. J Clin Invest 60:846–854, 1977
Carter SK: Adriamycin — a review. J Natl Cancer Inst 55:1265–1274, 1975
Alberts DS, Chen HSG: Tabular summary of pharmacokinetic parameters relevant to in vitro drug assay. In: SE Salmon (ed): Cloning of Human Tumor Stem Cells. Alan R. Liss, Inc., New York, 1980, pp 351–359
Miyamoto H, Inoue K, Arakawa M, Ogawa M: Chemosensitivity of adriamycin, mitomycin C and bleomycin with in vitro colony assay. Jap J Clin Oncol 9(11):1921–1927, 1982
Von Hoff DD, Coltman Jr CA, Forseth B: Activity of mitoxantrone in a human tumor cloning system. Cancer Res 41:1853–1855, 1981
Anderson KC, Cohen GI, Garnick MB: Phase II trial of mitoxantrone. Cancer Treat Rep 66(11):1929–1931, 1982
Ahmann FR, Meyskens FL, Moon TE, Durie BGM, Salmon SE: In vitro chemosensitivities of human tumor stem cells to the Phase II drug 4′-(9-acridinylamino)methanesulfon-m-anisidide and prospective in vivo correlations. Cancer Res 42:4495–4498, 1982
Legha SS, Keating MJ, Zander AR, McCredie KB, Bodey GP, Freireich EJ: 4′-(9-acridinylamino)methanesulfon-manisidide (AMSA): a new drug effective in the treatment of adult acute leukemia. Ann Int Med 93:17–21, 1980
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Inoue, K., Arakawa, M., Miyamoto, H. et al. Activity of 4′-0-tetrahydropyranyladriamycin hydrochloride (THP-ADM) in a human tumor cloning system. Invest New Drugs 1, 271–275 (1983). https://doi.org/10.1007/BF00177409
Issue Date:
DOI: https://doi.org/10.1007/BF00177409